KYVERNA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.32 USD | +13.07% |
|
-4.22% | 0.00% |
| Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
| Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Kyverna Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
19cf00456a00ccbe8.EFrRZq9z-oxCIFB3ueL6LXwh2tPSfal6vYUiuqClBQg.ZGzmVsUik8kzFSBEw7WOWTltqru6E94R9cpLzOPcVUcoarRV1xTX9jdNJw~390b059ceb7520bfcb62d03e0e0e4030
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.66
USD
Average target price
42.75
USD
Spread / Average Target
+237.68%
High Price Target
48
USD
Spread / Highest target
+279.15%
Low Price Target
39
USD
Spread / Lowest Target
+208.06%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Kyverna Therapeutics, Inc.
| Morgan Stanley | |
| JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- KYTX Stock
- Consensus Kyverna Therapeutics, Inc.